Biogen Shares Jump 3.6% Following Wells Fargo Upgrade and Drug Acquisition Deal

Biogen Stock Surges on Dual Positive Developments

Biogen Inc. (NASDAQ:BIIB) experienced a notable 3.6% surge during afternoon trading on Tuesday, driven by a combination of analyst optimism and strategic expansion news. The biotechnology company's stock climbed following a Wells Fargo upgrade and the announcement of acquiring exclusive global rights to a promising drug candidate.

Wells Fargo Boosts Confidence with Rating Upgrade

Wells Fargo analysts demonstrated renewed faith in Biogen's prospects by upgrading the stock to 'Overweight' from a previous rating and lifting their price target significantly to $250 from $200. The investment bank highlighted particular enthusiasm for the company's advanced-stage immunology and kidney disease programs, viewing these pipeline assets as catalysts that could drive growth beyond Biogen's current established product portfolio.

Strategic Acquisition Expands Global Reach

Simultaneously, Biogen announced the completion of its acquisition of worldwide exclusive rights to felzartamab, a drug candidate currently advancing through Phase 3 clinical trials. The company secured the remaining global licensing rights for the Greater China Region from TJ Biopharma, completing its worldwide coverage for this potential treatment.

Felzartamab is being investigated as a treatment option for multiple immune-mediated diseases, representing a significant expansion of Biogen's therapeutic focus areas. The financial terms of the agreement include an immediate $100 million upfront payment, with additional milestone payments potentially reaching $750 million based on developmental and commercial achievements.

Market Response and Trading Activity

Following the initial spike, Biogen shares settled at $183.27, maintaining a solid 3.3% gain from the previous closing price. This movement stands out for a stock that typically experiences limited volatility, with only five trading sessions showing moves exceeding 5% over the past twelve months.

The market's response suggests investors view these developments as materially significant for the company's trajectory, though analysts note it may not fundamentally alter the long-term investment thesis.

Recent Performance Context

Biogen's stock performance has faced headwinds recently, with the most recent significant decline occurring 18 days prior when shares dropped 3.5%. That movement was attributed to reports suggesting potential US tariffs of up to 100% on branded and patented drug imports, particularly targeting pharmaceutical companies that haven't negotiated drug price reduction agreements with US authorities.

Current Valuation and Historical Performance

Year-to-date, Biogen has generated a 3.1% return for shareholders, with the current price of $183.27 approaching the 52-week high of $201.18 reached in February 2026. However, the longer-term picture presents challenges, as investors who purchased $1,000 worth of shares five years ago would find their investment valued at approximately $670.81 today.

Looking Forward

The combination of analyst confidence and strategic asset expansion positions Biogen for potential growth acceleration. The Wells Fargo upgrade reflects broader optimism about the company's pipeline diversity, while the felzartamab acquisition demonstrates management's commitment to expanding therapeutic reach through strategic partnerships and licensing agreements.

Investors will likely monitor the progress of Phase 3 trials for felzartamab and other pipeline programs as key indicators of the company's ability to drive future revenue growth beyond its current franchise products.